{
    "organizations": [],
    "uuid": "562da9cc066b698047796b601531be7d8b9e80b2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-natco-pharma-files-anda-to-us-fda/brief-natco-pharma-files-anda-to-u-s-fda-for-sofosbuvir-tablets-idUSFWN1QJ0EA",
    "ord_in_thread": 0,
    "title": "Natco Pharma Files ANDA to U.S. FDA For Sofosbuvir Tablets",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - Natco Pharma Ltd:\n* SAYS FILED AN ABBREVIATED NEW DRUG APPLICATION FOR SOFOSBUVIR TABLETS, 400MG, WITH U.S.‍​ FDA\n* SAYS DRUG IS USED FOR TREATMENT OF CHRONIC HEPATITIS C INFECTION Source text: bit.ly/2F5vduT\n ",
    "published": "2018-03-01T16:02:00.000+02:00",
    "crawled": "2018-03-02T20:15:04.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "natco",
        "pharma",
        "ltd",
        "say",
        "filed",
        "abbreviated",
        "new",
        "drug",
        "application",
        "sofosbuvir",
        "tablet",
        "400mg",
        "fda",
        "say",
        "drug",
        "used",
        "treatment",
        "chronic",
        "hepatitis",
        "c",
        "infection",
        "source",
        "text"
    ]
}